Welcome to our dedicated page for Rocket Pharmaceu news (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceu stock.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company developing investigational genetic therapies for rare and often life-threatening disorders. The RCKT news feed on Stock Titan aggregates company announcements, press releases and third-party coverage related to its AAV and lentiviral gene therapy programs.
Investors following Rocket’s news can track updates on its adeno-associated viral (AAV) cardiovascular portfolio, which includes RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM) and RP-A701 for BAG3-associated dilated cardiomyopathy (BAG3-DCM). News items frequently cover clinical trial milestones, such as FDA lifting a clinical hold on the pivotal Phase 2 trial of RP-A501, preliminary Phase 1 data for RP-A601, and IND clearance and Fast Track designation for RP-A701.
The news stream also highlights developments in Rocket’s lentiviral (LV) hematology portfolio, including regulatory progress for KRESLADI (marnetegragene autotemcel; marne-cel) in severe leukocyte adhesion deficiency-I (LAD-I). Articles may discuss FDA acceptance of the resubmitted Biologics License Application (BLA), the setting of a Prescription Drug User Fee Act (PDUFA) target action date, and clinical data showing survival and infection outcomes in treated patients.
Beyond pipeline updates, RCKT news includes financial results, strategic corporate reorganization and pipeline prioritization announcements, leadership and board changes, equity inducement grants and participation in major healthcare investor conferences. By reviewing this page regularly, readers can follow how Rocket’s clinical, regulatory and corporate events may influence sentiment around RCKT stock and gain context on the company’s progress in gene therapy for rare cardiovascular and hematologic diseases.
Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Gaurav Shah, M.D., the company's CEO, will deliver a presentation on Monday, January 13, at 3:45 p.m. PT and will be available for investor meetings throughout the conference.
The presentation will be accessible via webcast and will be made available on the company's website in the Investors section. Rocket Pharmaceuticals specializes in developing sustainable pipeline solutions for rare disorders with high unmet medical needs.
Rocket Pharmaceuticals (NASDAQ: RCKT) has announced the pricing of an upsized public offering of 13,200,000 shares of common stock at $12.50 per share. The offering is expected to generate gross proceeds of $165 million before deducting underwriting costs and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,980,000 shares. The offering is anticipated to close around December 12, 2024. Morgan Stanley, Leerink Partners, and Cantor are serving as joint book-running managers, with LifeSci Capital acting as lead manager.
Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, has announced plans for a $150 million public offering of common stock. The company will grant underwriters a 30-day option to purchase up to an additional 15% of shares. Morgan Stanley, Leerink Partners, and Cantor are serving as joint book-running managers, with LifeSci Capital as lead manager.
The offering will be conducted through a previously filed shelf registration statement with the SEC. The final terms and completion of the offering are subject to market conditions.
Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, announced its participation in the 7th Annual Evercore HealthCONx Conference in Miami, Florida. CEO Gaurav Shah will conduct a fireside chat on Tuesday, December 3, at 1:45 p.m. ET and hold investor meetings throughout the day. The fireside chat will be accessible via webcast and will be available on the company's Investors section of their website.
Rocket Pharmaceuticals (NASDAQ: RCKT) presented long-term Phase 1 data for RP-A501 in Danon disease patients at the American Heart Association Scientific Sessions 2024. The results, also published in The New England Journal of Medicine, showed that all six evaluable patients remained alive and transplant-free, with sustained LAMP2 protein expression and ≥10% reduction in LV mass index at 12 months, maintained through follow-up of up to five years.
Key findings include cardiac LAMP2 expression in all evaluable patients, improvements in heart failure classification from NYHA Class II to Class I, significant reductions in cardiac biomarkers (84% median reduction in troponin, 57% in BNP), and enhanced quality of life scores (27-point median increase in KCCQ) at 24-54 months post-treatment.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced it will present new data from its RP-A501 Phase 1 trial for Danon disease at the American Heart Association's 2024 Late-Breaking Science sessions in Chicago. The presentation, titled 'Danon Disease Phase 1 RP-A501 Results: The First Single-Dose Intravenous Gene Therapy with Recombinant Adeno-Associated Virus (AAV9:LAMP2B) for a Monogenic Cardiomyopathy,' will be delivered by Dr. Joseph Rossano from Children's Hospital of Philadelphia on November 18, 2024. The company will also host an investor webinar following the presentation.
Rocket Pharmaceuticals (NASDAQ: RCKT), a late-stage biotechnology company focused on genetic therapies for rare disorders, announced its participation in the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. CEO Gaurav Shah will participate in a fireside chat on Tuesday, November 12, at 5:00 p.m. PT. The event will be accessible via webcast through the company's Investors section website.
Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q3 2024 financial results and pipeline updates. Key developments include completed enrollment in Phase 2 pivotal study of RP-A501 for Danon disease and low-dose cohort completion for RP-A601 PKP2-ACM study. The company initiated rolling BLA submission for RP-L102 and expects KRESLADI approval in 2025. Financial highlights show cash position of $235.7M expected to fund operations into 2026. R&D expenses decreased to $133.9M from $144.6M year-over-year, while G&A expenses increased to $76.6M from $51.8M. Net loss was $198.4M or $2.11 per share.
Rocket Pharmaceuticals (NASDAQ: RCKT) has completed enrollment in its global Phase 2 pivotal trial of RP-A501 for treating male patients with Danon disease. The trial enrolled 12 patients, including a two-patient safety run-in, with the remaining 10 patients enrolled across the U.S. and EU within three months. The study aims to evaluate the efficacy and safety of RP-A501, a one-time treatment designed to improve cardiac abnormalities associated with Danon disease.
The trial's co-primary endpoints are improvements in LAMP2 protein expression and reductions in left ventricular mass. Key secondary endpoints include changes in troponin, natriuretic peptides, and event-free survival to 24 months. Rocket Pharmaceuticals plans to pursue regulatory filings simultaneously in the U.S. and ex-U.S. markets, given the prevalence of Danon disease across regions.
Rocket Pharmaceuticals (NASDAQ: RCKT) has appointed Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is currently the Chief Scientific Officer and President of Research & Development at Pfizer Inc. (NYSE: PFE), focusing on advancing gene therapies, small-molecule medicines, biotherapeutics, and vaccines. His extensive experience includes leadership roles at Wyeth, Boehringer Ingelheim, AstraZeneca, Pharmacia, and Upjohn.
Dr. Dolsten is a member of the Board of Overseers for the Scripps Research Institute and a Foreign Member of The Royal Swedish Academy of Engineering Sciences. He has also advised the Obama administration on regulatory and drug development issues and Vice President Biden's Cancer Moonshot Initiative. This appointment aims to strengthen Rocket's scientific capabilities and support its mission to develop transformative treatments for rare disorders.